Related references
Note: Only part of the references are listed.Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment
Sadahisa Ogasawara et al.
INVESTIGATIONAL NEW DRUGS (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study
Masatoshi Kudo et al.
LIVER INTERNATIONAL (2016)
Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice
Amit G. Singal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
et al.
JOURNAL OF HEPATOLOGY (2015)
Hepatocellular carcinoma: clinical frontiers and perspectives
Jordi Bruix et al.
GUT (2014)
Effect of treatment with branched-chain amino acids during sorafenib therapy for unresectable hepatocellular carcinoma
Haruhiko Takeda et al.
HEPATOLOGY RESEARCH (2014)
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
Masatoshi Kudo et al.
LIVER CANCER (2014)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study
Hisashi Hidaka et al.
JOURNAL OF GASTROENTEROLOGY (2012)
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses
Jean-Luc Raoul et al.
JOURNAL OF HEPATOLOGY (2012)
Treatment of Advanced Hepatocellular Carcinoma with Emphasis on Hepatic Arterial Infusion Chemotherapy and Molecular Targeted Therapy
Masatoshi Kudo
LIVER CANCER (2012)
Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma
Jihye Cha et al.
LIVER CANCER (2012)
Management of Hepatocellular Carcinoma: An Update
Jordi Bruix et al.
HEPATOLOGY (2011)
Arterial-phase contrast-enhanced ultrasonography for evaluating anti-angiogenesis treatment: A pilot study
Keiko Yoshida et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion
Kang Mo Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
Mao-Bin Meng et al.
RADIOTHERAPY AND ONCOLOGY (2009)
Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis
Kwang-Hyub Han et al.
CANCER (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Three-dimensional conformal radiotherapy for the treatment of arteriovenous shunting in patients with hepatocellular carcinoma
H. C. Hsu et al.
BRITISH JOURNAL OF RADIOLOGY (2007)
Share Paper
